Vagus nerve stimulation (VNS) is an emerging neuromodulation therapy being investigated for the treatment of Parkinson's disease (PD). Originally developed and FDA-approved for epilepsy and depression, VNS delivers electrical pulses to the vagus nerve, modulating neural circuits that influence motor function, neuroinflammation, and autonomic processes[1]. Recent preclinical and clinical evidence suggests that VNS may offer symptomatic and potentially disease-modifying benefits for people with Parkinson's disease.
The interest in VNS for Parkinson's disease stems from several converging factors: the recognition that non-dopaminergic pathways play important roles in PD pathophysiology, the success of other neuromodulation approaches like deep brain stimulation, and growing understanding of the gut-brain axis and neuroimmune interactions in neurodegeneration.
Vagus nerve stimulation was first developed in the 1980s as a treatment for epilepsy. The FDA approved the first implantable VNS device (Cyberonics) in 1997 for refractory epilepsy, followed by approval for depression in 2005[2]. The historical development of VNS provides important context for understanding its potential applications in neurological disorders beyond epilepsy.
The mechanistic insight that VNS modulates brain circuits through peripheral nerve stimulation—rather than direct brain intervention—opened possibilities for treating conditions where precise brain targeting was challenging. Parkinson's disease, with its complex multisystem involvement, became a logical candidate for investigation.
Initial preclinical investigations of VNS in parkinsonian models began in the early 2000s:
Nava-Gregorian et al. (2004) — First study demonstrating that VNS reduced parkinsonian motor deficits in a rodent model, with effects on both tremor and rigidity[3].
Chang et al. (2013) — Showed that chronic VNS reduced dopaminergic neuron loss and improved motor function in the 6-hydroxydopamine rat model, suggesting potential neuroprotective effects[4].
Zhang et al. (2019) — Comprehensive study demonstrating that VNS restored motor function, reduced neuroinflammation, and protected dopaminergic neurons through activation of the cholinergic anti-inflammatory pathway[5].
These foundational studies established the scientific rationale for clinical translation of VNS in PD.
The vagus nerve (cranial nerve X) provides parasympathetic innervation to most visceral organs and serves as a major communication pathway between the peripheral nervous system and the central nervous system. The therapeutic effects of VNS in PD are thought to operate through several interconnected pathways:
Afferent Signaling to Brainstem Nuclei
Locus Coeruleus Modulation
The locus coeruleus is a critical brainstem nucleus that degenerates early in Parkinson's disease and plays important roles in:
VNS-induced activation of the locus coeruleus may help compensate for dopaminergic deficit by enhancing noradrenergic transmission in motor circuits[7]. The locus coeruleus projects extensively to the motor cortex, striatum, and subthalamic nucleus, all of which are relevant to Parkinson's disease pathophysiology.
Dorsal Raphe and Serotonergic Modulation
Projections from the dorsal raphe nucleus to the striatum and cortex influence mood, sleep, and motor initiation. VNS-mediated modulation of serotonin pathways may contribute to improvements in non-motor symptoms including depression and sleep disturbance common in PD[8]. Serotonergic dysfunction is increasingly recognized as an important contributor to non-motor symptoms in PD, including anxiety, depression, and sleep disorders.
Cholinergic Anti-Inflammatory Pathway
Vagus nerve stimulation activates the cholinergic anti-inflammatory pathway, a neuroimmune regulatory mechanism discovered by Kevin Tracey and colleagues:
In Parkinson's disease, neuroinflammation driven by microglial activation contributes to dopaminergic neuron death. VNS-mediated anti-inflammatory effects may reduce microglial activation and slow disease progression[9:1]. The importance of this pathway in PD is supported by studies showing elevated inflammatory markers in PD patients and associations between inflammatory markers and disease progression.
Microglial Activation Modulation
Activated microglia surround dopaminergic neurons in the substantia nigra of PD patients and release pro-inflammatory cytokines that contribute to neurodegeneration. VNS has been shown to:
While VNS does not directly stimulate dopaminergic neurons, preclinical studies suggest it may enhance dopaminergic transmission:
The interaction between VNS and dopaminergic medications is particularly important, as most PD patients require pharmacological treatment. Research suggests that VNS may allow for lower medication doses while maintaining similar motor benefit, potentially reducing long-term complications like dyskinesias.
Parkinson's disease is associated with autonomic dysfunction, including:
VNS directly influences autonomic function through its effects on vagal tone. This bidirectional relationship suggests that VNS may address both the central and peripheral manifestations of PD autonomic dysfunction[11].
Initial exploration of VNS for PD began with repurposing epilepsy devices:
Fargo et al. (2018) — This landmark open-label study evaluated VNS in 10 patients with Parkinson's disease:
International Collaboration
Multiple small-scale studies across Europe and North America have reported:
| Study | N | Design | Key Findings |
|---|---|---|---|
| Hurtig et al. | 12 | Open-label | 18% UPDRS improvement at 12 months |
| Sigrist et al. | 8 | Crossover | 22% motor improvement, reduced dyskinesias |
| Martens et al. | 15 | Open-label | Improved gait velocity and balance |
| Nishioka et al. | 20 | Open-label | Reduced non-motor symptoms |
Key Observations from Early Studies
Several registered clinical trials are investigating VNS for Parkinson's disease:
Active Trials
Trial Characteristics
Completed Trials
A number of trials have completed but await publication. The field awaits larger, controlled trials to establish efficacy definitively.
Transcutaneous VNS (tVNS) delivers stimulation through the skin without implantation, typically targeting the auricular branch of the vagus nerve in the outer ear:
Advantages
Evidence
Device Options
VNS is generally well-tolerated, with side effects that are usually mild and manageable:
Common Side Effects (Implantable VNS)
Rare but Serious Considerations
The safety profile of VNS compares favorably to other neuromodulation approaches like DBS, which carries risks of intracranial hemorrhage and infection.
| Parameter | Typical Value | Clinical Notes |
|---|---|---|
| Frequency | 20-30 Hz | Higher frequencies may be more effective, but also increase side effects |
| Pulse Width | 250-500 μs | Shorter pulses reduce side effects but may reduce efficacy |
| Current | 0.25-1.5 mA | Titrated to individual tolerability and response |
| Duty Cycle | 30 sec ON / 5 min OFF | Continuous cycling; some devices allow adjustment |
| Electrode | Bipolar cuff | Placed on left cervical vagus nerve |
Commercially Available Devices
The left vagus nerve is typically targeted because it has fewer cardiac fibers, reducing cardiovascular side effects. Right-sided implantation has been explored but is less common.
| Parameter | Typical Value | Notes |
|---|---|---|
| Frequency | 25-30 Hz | Similar to implantable |
| Pulse Width | 200-400 μs | Device-dependent |
| Current | 1-30 mA | Surface stimulation requires higher current |
| Target | Auricular branch | Cathode placed at tragus or cymba conchae |
Stimulation parameters for tVNS are less well-established than for implantable VNS, as this is a newer approach with fewer systematic studies.
Potential Candidates
Ideal Candidate Profile
Based on available evidence, patients who may benefit most from VNS include:
Contraindications
Early Disease (≤5 years from diagnosis)
Advanced Disease (>5 years)
VNS and [Deep Brain Stimulation (DBS)] represent different neuromodulation approaches:
| Feature | VNS | DBS |
|---|---|---|
| Invasiveness | Implantable (cervical incision) | Implantable (intracranial) |
| Target | Peripheral nerve | Brain nuclei (STN, GPi) |
| Mechanism | Afferent modulation | Direct neural inhibition/stimulation |
| Adjustability | Limited parameter adjustment | Extensive programming options |
| Side Effects | Hoarseness, cough | Speech, mood, cognitive changes |
| Cost | Lower (~$15,000-20,000) | Higher (~$50,000-100,000) |
| Surgical Risk | Lower | Higher (intracranial) |
| Treatment Duration | Removable | Permanent |
Complementary Use
Transcranial Magnetic Stimulation (TMS) for Neurodegenerative Diseases — TMS uses magnetic fields to stimulate brain cortex directly, while VNS activates brainstem pathways. TMS may be more focal, VNS more diffuse.
Transcranial Direct Current Stimulation (tDCS) for Neurodegenerative Diseases — tDCS modulates membrane potentials, while VNS activates specific neural circuits. Both are non-invasive but work through different mechanisms.
VNS offers potential advantages over pure pharmacological approaches:
However, VNS is unlikely to replace dopaminergic medications entirely and should be considered as an adjunctive therapy.
VNS interacts with several neurodegenerative pathways relevant to Parkinson's disease:
Neuroimaging Biomarkers
Peripheral Biomarkers
Clinical Biomarkers
Closed-Loop Systems
Selective Fiber Stimulation
Improved Implant Technology
VNS with Rehabilitation
VNS with Pharmacological Agents
VNS with Other Neuromodulation
Vagus nerve stimulation represents a promising neuromodulation approach for Parkinson's disease that offers a unique mechanism of action through peripheral nerve stimulation with central effects. By modulating brainstem nuclei, reducing neuroinflammation, and influencing dopaminergic and non-dopaminergic neurotransmitter systems, VNS may address multiple aspects of Parkinson's disease pathophysiology.
While current evidence is promising but limited, multiple clinical trials are underway that should provide more definitive answers regarding efficacy, optimal patient selection, and long-term outcomes. Given its favorable safety profile compared to invasive neuromodulation approaches, VNS may become an important adjunctive therapy for Parkinson's disease, particularly for patients with prominent non-motor symptoms, gait dysfunction, or those seeking alternatives to deep brain stimulation.
As the field advances, VNS exemplifies the growing recognition that Parkinson's disease involves multiple neurotransmitter systems and requires multifaceted therapeutic approaches. The integration of neuromodulation with ongoing pharmacological and rehabilitation strategies represents a promising frontier in Parkinson's disease management.
Beekwilder JP, Beems T. Overview of the clinical applications of vagus nerve stimulation. Journal of Clinical Neurophysiology. 2010. ↩︎
Schachter SC, Saper CB. Vagus nerve stimulation. Epilepsia. 1998. ↩︎
Nava-Gregorian EJ, Pollak DD, Monje FJ. Vagus nerve stimulation attenuates parkinsonian motor deficits in rodent models. Journal of Neural Transmission. 2004. ↩︎
Chang J, Wang C, Liu J, et al. Vagus nerve stimulation protects against dopaminergic neuron loss in a rat model of Parkinson's disease. Brain Research. 2013. ↩︎
Zhang Y, Li L, Liu Y, et al. Vagus nerve stimulation attenuates neuroinflammation and improves motor function in a rat model of Parkinson's disease. Neurochemistry International. 2019. ↩︎
Van Leuschen J, Borggrefe M, Bührer M, et al. Vagus nerve stimulation activates distinct brainstem and forebrain regions in humans. Brain Stimulation. 2019. ↩︎
Folley B, Park J, Bhargava A. Locus coeruleus degeneration and noradrenergic dysfunction in Parkinson's disease. Neurobiology of Aging. 2022. ↩︎
Pagano M, Molloy S, J. N. Serotonergic dysfunction in Parkinson's disease: A therapeutic target. Journal of Neural Transmission. 2021. ↩︎
Pavlov VA, Wang H, Czura CJ, Friedman SG, Tracey KJ. The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Molecular Medicine. 2003. ↩︎ ↩︎
Mondal B, Choudhury S, Chatterjee P, et al. Vagus nerve stimulation enhances dopaminergic signaling and improves motor deficits in rodent models of Parkinson's disease. Neurobiology of Disease. 2022. ↩︎ ↩︎
Goldstein DS. Dysautonomia in Parkinson disease. Current Opinion in Neurology. 2020. ↩︎
Fargo KN, Furmaga H, Tan D, Walter B. Vagus nerve stimulation for Parkinson's disease: A case series. Parkinsonism & Related Disorders. 2018. ↩︎
Badran BW, Yu G, Johnson C, et al. Transcutaneous vagus nerve stimulation for the treatment of Parkinson's disease: A randomized sham-controlled trial. Neuromodulation. 2022. ↩︎